<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03921476</url>
  </required_header>
  <id_info>
    <org_study_id>BJS07172018</org_study_id>
    <nct_id>NCT03921476</nct_id>
  </id_info>
  <brief_title>Acne and Mood: Impact of Treatment on Depression, Anxiety, and Sexual Function</brief_title>
  <official_title>Acne and Mood: Impact of Treatment on Depression, Anxiety, and Sexual Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to examine if there is any relationship between spironolactone use
      prescribed for acne vulgaris and depression, anxiety, and/or sexual function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent correlation between spironolactone use for acne vulgaris and increased prevalence of depression.</measure>
    <time_frame>one week</time_frame>
    <description>Score for depression from subject reported Dermatology Life Quality Index (DLQI) survey</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent correlation between spironolactone use for acne vulgaris and increased prevalence of anxiety.</measure>
    <time_frame>two weeks</time_frame>
    <description>Score for depression from subject reported Generalized Anxiety Disorder (GAD-7) survey</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent correlation between spironolactone use for acne vulgaris and increased prevalence of sexual dysfunction.</measure>
    <time_frame>four weeks</time_frame>
    <description>Score for depression from subject reported Female Sexual Function Index (FSFI) survey.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Subjects on spironolactone for a diagnosis of acne vulgaris</arm_group_label>
    <description>Female subjects between 18 and 65 years of age currently taking spironolactone for a diagnosis of acne vulgaris</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects on oral antibiotics for a diagnosis of acne vulgaris</arm_group_label>
    <description>Female subjects between 18 and 65 years of age currently taking oral antibiotics for a diagnosis of acne vulgaris</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Online survey</intervention_name>
    <description>Online survey completion through Northwestern's REDCap</description>
    <arm_group_label>Subjects on oral antibiotics for a diagnosis of acne vulgaris</arm_group_label>
    <arm_group_label>Subjects on spironolactone for a diagnosis of acne vulgaris</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients who have acne vulgaris being treated with spironolactone or oral
        antibiotics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Female subjects between 18 and 65 years of age currently taking spironolactone for a
        diagnosis of acne vulgaris

        OR

        Female subjects between 18 and 65 years of age currently taking oral antibiotics for a
        diagnosis of acne vulgaris

        AND Subjects able to complete an online survey in English

        Exclusion Criteria:

        Subjects less than 18 years of age or older than 65 years of age Subjects that have ever
        been diagnosed with any mood disorder by a clinician prior to starting spironolactone
        (history of mood disorder or current mood disorder) Subjects taking hormonal contraception
        (including but not limited to oral contraceptive pills) for a duration of less than 6
        months Subjects that have ever been diagnosed with any type of sexual dysfunction prior to
        starting spironolactone Subjects not able to complete an online survey in English Subjects
        taking oral isotretinoin for a diagnosis of acne Subjects that are currently pregnant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Biologically female subjects</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bethanee Schlosser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dermatology CTU</last_name>
    <phone>312-503-5944</phone>
    <email>NUdermatologyCTU@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dermatology CTU</last_name>
      <phone>312-503-5944</phone>
      <email>NUdermatologyCTU@northwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Bethanee Schlosser</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

